Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Rhythm Pharmaceuticals

DB:1RV
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1RV
DB
$635M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Rhythm Pharmaceuticals has significant price volatility in the past 3 months.
1RV Share Price and Events
7 Day Returns
7%
DB:1RV
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-44%
DB:1RV
-13.2%
DE Biotechs
-20.9%
DE Market
1RV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rhythm Pharmaceuticals (1RV) 7% -18.5% -30.8% -44% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 1RV underperformed the Biotechs industry which returned -13.2% over the past year.
  • 1RV underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
1RV
Industry
5yr Volatility vs Market
Related Companies

1RV Value

 Is Rhythm Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Rhythm Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Rhythm Pharmaceuticals.

DB:1RV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1RV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (0.56%))
1.129
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.129 * 5.44%)
5.75%

Discounted Cash Flow Calculation for DB:1RV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Rhythm Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:1RV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.75%)
2020 -332.00 Analyst x1 -313.94
2021 -83.00 Analyst x1 -74.21
2022 116.00 Analyst x1 98.08
2023 185.00 Analyst x1 147.91
2024 314.00 Analyst x1 237.38
2025 417.96 Est @ 33.11% 298.78
2026 514.34 Est @ 23.06% 347.68
2027 596.76 Est @ 16.02% 381.44
2028 663.00 Est @ 11.1% 400.72
2029 713.74 Est @ 7.65% 407.92
Present value of next 10 years cash flows $1,931.00
DB:1RV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $713.74 × (1 + -0.39%) ÷ (5.75% – -0.39%)
$11,571.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $11,571.75 ÷ (1 + 5.75%)10
$6,613.55
DB:1RV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,931.00 + $6,613.55
$8,544.55
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $8,544.55 / 44.06
$193.93
DB:1RV Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1RV represents 0.95073x of NasdaqGM:RYTM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.95073x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 193.93 x 0.95073
€184.38
Value per share (EUR) From above. €184.38
Current discount Discount to share price of €13.70
= -1 x (€13.70 - €184.38) / €184.38
92.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Rhythm Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €13.7 vs Future cash flow value of €184.38
Current Discount Checks
For Rhythm Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Rhythm Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Rhythm Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rhythm Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rhythm Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1RV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.86
NasdaqGM:RYTM Share Price ** NasdaqGM (2020-04-03) in USD $14.41
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rhythm Pharmaceuticals.

DB:1RV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RYTM Share Price ÷ EPS (both in USD)

= 14.41 ÷ -3.86

-3.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rhythm Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Rhythm Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Rhythm Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:1RV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
58.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rhythm Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rhythm Pharmaceuticals's assets?
Raw Data
DB:1RV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.39
NasdaqGM:RYTM Share Price * NasdaqGM (2020-04-03) in USD $14.41
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:1RV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RYTM Share Price ÷ Book Value per Share (both in USD)

= 14.41 ÷ 6.39

2.26x

* Primary Listing of Rhythm Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rhythm Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Rhythm Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Rhythm Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1RV Future Performance

 How is Rhythm Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rhythm Pharmaceuticals expected to grow at an attractive rate?
  • Rhythm Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Rhythm Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Rhythm Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1RV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1RV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 58.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1RV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1RV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 659 355 338 4
2023-12-31 468 183 246 4
2022-12-31 219 66 47 6
2021-12-31 65 -135 -101 8
2020-12-31 6 -171 -149 7
2020-04-06
DB:1RV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -123 -141
2019-09-30 -112 -133
2019-06-30 -95 -115
2019-03-31 -82 -87
2018-12-31 -62 -74
2018-09-30 -49 -59
2018-06-30 -40 -53
2018-03-31 -34 -47
2017-12-31 -29 -38
2017-09-30 -28 -36
2017-06-30 -24 -32
2017-03-31 -24 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Rhythm Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Rhythm Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1RV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Rhythm Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1RV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 6.03 9.29 3.14 4.00
2023-12-31 3.55 6.53 0.96 4.00
2022-12-31 0.80 2.89 -1.33 5.00
2021-12-31 -2.11 -0.96 -3.31 7.00
2020-12-31 -3.34 -2.61 -4.35 7.00
2020-04-06
DB:1RV Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.86
2019-09-30 -3.87
2019-06-30 -3.34
2019-03-31 -2.64
2018-12-31 -2.39
2018-09-30 -2.04
2018-06-30 -2.41
2018-03-31 -2.65
2017-12-31 -2.83
2017-09-30 -3.91
2017-06-30 -3.13
2017-03-31 -2.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rhythm Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Rhythm Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rhythm Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1RV Past Performance

  How has Rhythm Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rhythm Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rhythm Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Rhythm Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rhythm Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Rhythm Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rhythm Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1RV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -140.73 36.55 109.45
2019-09-30 -133.28 35.52 103.40
2019-06-30 -114.96 33.53 87.54
2019-03-31 -86.58 31.12 60.81
2018-12-31 -74.06 28.08 50.34
2018-09-30 -59.18 24.02 38.23
2018-06-30 -52.92 17.80 33.49
2018-03-31 -46.52 12.72 30.31
2017-12-31 -37.58 9.52 22.89
2017-09-30 -36.14 7.93 21.87
2017-06-30 -31.90 6.60 21.32
2017-03-31 -30.42 6.36 20.55
2016-12-31 -29.07 6.31 19.59
2016-09-30 -26.65 5.59 17.58
2016-06-30 -22.90 5.53 14.36
2016-03-31 -17.28 4.66 10.40
2015-12-31 -12.00 3.43 7.15
2015-09-30 -6.01 1.54 4.15
2015-06-30 -2.82 0.93 1.89
2015-03-31 -4.66 1.07 3.59
2014-12-31 -6.49 1.21 5.28
2013-12-31 -12.20 1.70 10.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rhythm Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rhythm Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rhythm Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rhythm Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rhythm Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1RV Health

 How is Rhythm Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rhythm Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rhythm Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rhythm Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rhythm Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Rhythm Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rhythm Pharmaceuticals Company Filings, last reported 3 months ago.

DB:1RV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 281.02 0.00 292.46
2019-09-30 149.12 0.00 162.44
2019-06-30 181.47 0.00 195.17
2019-03-31 220.49 0.00 221.52
2018-12-31 246.26 0.00 252.06
2018-09-30 269.64 0.00 272.39
2018-06-30 284.32 0.00 287.55
2018-03-31 133.66 0.00 136.45
2017-12-31 144.79 0.00 148.08
2017-09-30 29.09 0.00 30.42
2017-06-30 15.29 0.00 17.74
2017-03-31 21.58 0.00 23.88
2016-12-31 7.30 0.00 10.54
2016-09-30
2016-06-30
2016-03-31 32.00 0.00 34.87
2015-12-31 32.00 0.00 34.87
2015-09-30 22.77 0.00 23.91
2015-06-30 -0.40 0.00 0.17
2015-03-31 -0.40 0.00 0.17
2014-12-31 -0.36 0.00 0.15
2013-12-31 -1.35 0.00 0.24
  • Rhythm Pharmaceuticals has no debt.
  • Rhythm Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rhythm Pharmaceuticals has sufficient cash runway for 2.3 years based on current free cash flow.
  • Rhythm Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 50% each year.
X
Financial health checks
We assess Rhythm Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rhythm Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1RV Dividends

 What is Rhythm Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rhythm Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Rhythm Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rhythm Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rhythm Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1RV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1RV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rhythm Pharmaceuticals has not reported any payouts.
  • Unable to verify if Rhythm Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rhythm Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rhythm Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Rhythm Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Rhythm Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rhythm Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rhythm Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1RV Management

 What is the CEO of Rhythm Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hunter Smith
COMPENSATION $1,587,137
AGE 50
TENURE AS CEO 0.1 years
CEO Bio

Mr. Hunter C. Smith has been the Chief Financial Officer at Rhythm Pharmaceuticals, Inc. since July 31, 2017 and served its Treasurer since August 2017 respectively. Mr. Smith serves as Interim Chief Executive Officer at Rhythm Pharmaceuticals, Inc. since March 2020. Mr. Smith has been the Chief Financial Officer of Rhythm Holding Company, LLC since August 1, 2017. He has many global finance and management experience across multiple industries and financial disciplines, included expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. Mr. Smith served as Vice President of Finance and Chief Financial Officer of the Inflammation and Immunology Business Unit of Celgene Corporation from 2013 to July 2017. Mr. Smith provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene and led global business planning and analysis for commercial affiliates and clinical study activities in over 16 countries. He held various roles during a 14-year tenure (1999 to 2013) at Bunge Limited, including Chief Financial Officer of two distinct business units, Corporate Treasurer and Chief Risk Officer. He served as Regional Chief Financial Officer for Asia at Bunge Limited since July 21, 2003 and its Director of Investor Relations and Global Communications. He served as the Chief Financial Officer of Bunge's Sugar and Bioenergy Segment. He joined Bunge in 1998 as Assistant Treasurer. He started his career at Manufacturers Hanover Trust Company. He has been an Independent Director of Genessee & Wyoming Inc. since March 27, 2015. He served as a Director of UBS AG. Mr. Smith has a B.A. in History, with honors, from Northwestern University and MBA in Finance from the Stern School of Business at New York University.

CEO Compensation
  • Hunter's compensation has increased whilst company is loss making.
  • Hunter's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Rhythm Pharmaceuticals management team in years:

1.7
Average Tenure
50
Average Age
  • The average tenure for the Rhythm Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Hunter Smith

TITLE
Interim CEO & CFO
COMPENSATION
$2M
AGE
50
TENURE
0.1 yrs

David Connolly

TITLE
Head of Investor Relations & Corporate Communications

Simon Kelner

TITLE
Chief Human Resources Officer
AGE
46
TENURE
1.8 yrs

Nithya Desikan

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
40
TENURE
2.8 yrs

Murray Stewart

TITLE
Chief Medical Officer
AGE
58
TENURE
1.5 yrs

Alastair Garfield

TITLE
Vice President of Translational Research & Development

John Hulburt

TITLE
Controller
AGE
52
Board of Directors Tenure

Average tenure and age of the Rhythm Pharmaceuticals board of directors in years:

5
Average Tenure
65
Average Age
  • The tenure for the Rhythm Pharmaceuticals board of directors is about average.
Board of Directors

David Meeker

TITLE
Independent Chairman of the Board
COMPENSATION
$282K
AGE
65
TENURE
3 yrs

Davie McGirr

TITLE
Independent Director
COMPENSATION
$255K
AGE
65
TENURE
4.4 yrs

Lee Kaplan

TITLE
Chairman of Scientific Advisory Board

Christophe Jean

TITLE
Independent Director
COMPENSATION
$244K
AGE
63
TENURE
5 yrs

Todd Foley

TITLE
Independent Director
COMPENSATION
$241K
AGE
47
TENURE
5.8 yrs

Ed Mathers

TITLE
Independent Director
COMPENSATION
$240K
AGE
59
TENURE
7.1 yrs

John Amatruda

TITLE
Member of Scientific Advisory Board
AGE
74

Michael Camilleri

TITLE
Member of Scientific Advisory Board

William Chin

TITLE
Member of Scientific Advisory Board

Liz Stoner

TITLE
Member of Scientific Advisory Board
AGE
69
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Rhythm Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rhythm Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1RV News

Simply Wall St News

1RV Company Info

Description

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company’s lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin POMC and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. operates as a subsidiary of Allergan GI Corp.

Details
Name: Rhythm Pharmaceuticals, Inc.
1RV
Exchange: DB
Founded: 2008
$588,478,501
44,058,909
Website: http://www.rhythmtx.com
Address: Rhythm Pharmaceuticals, Inc.
500 Boylston Street,
11th Floor,
Boston,
Massachusetts, 02116,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RYTM Common Stock Nasdaq Global Market US USD 05. Oct 2017
DB 1RV Common Stock Deutsche Boerse AG DE EUR 05. Oct 2017
BMV RYTM * Common Stock Bolsa Mexicana de Valores MX MXN 05. Oct 2017
Number of employees
Current staff
Staff numbers
70
Rhythm Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 03:08
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.